Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib

Journal of the American College of Cardiology

Volumn 66, Issue 20, 2015, Pages 2201-2210

  Nicholls, Stephen J ^a   Ruotolo, Giacomo ^b   Brewer, H Bryan ^c   Kane, John P ^d   Wang, Ming Dauh ^b   Krueger, Kathryn A ^b   Adelman, Steven J ^e   Nissen, Steven E ^f   Rader, Daniel J ^g  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ELI LILLY AND COMPANY   (United States)

^c MEDSTAR HEALTH RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Vascular Strategies   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

apolipoproteins; cholesterol; lipoproteins

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; EVACETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRE BETA 1 HIGH DENSITY LIPOPROTEIN; PRE BETA HIGH DENSITY LIPOPROTEIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; ABCA1 PROTEIN, HUMAN; BENZODIAZEPINE DERIVATIVE; CETP PROTEIN, HUMAN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ANALYTICAL PARAMETERS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL EFFLUX CAPACITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DYSLIPIDEMIA; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DYSLIPIDEMIAS; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; ATP BINDING CASSETTE TRANSPORTER 1; BENZODIAZEPINES; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 84946763626     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.09.013     Document Type: Article

References (33)

1. M.H. Davidson, J.M. McKenney, C.L. Shear, and et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels J Am Coll Cardiol 48 2006 1774 1781
2. J.M. McKenney, M.H. Davidson, C.L. Shear, and et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin J Am Coll Cardiol 48 2006 1782 1790
3. D. Bloomfield, G.L. Carlson, A. Sapre, and et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients Am Heart J 157 2009 352 360
4. S.J. Nicholls, H.B. Brewer, J.J. Kastelein, and et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
5. A.E. Di, N. Sarwar, P. Perry, and et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
6. G.G. Schwartz, A.G. Olsson, M. Abt, and et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
7. B.F. Voight, G.M. Peloso, M. Orho-Melander, and et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study Lancet 380 2012 572 580
8. M.J. Landray, R. Haynes, J.C. Hopewell, and et al. Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
9. P.J. Barter, M. Caulfield, M. Eriksson, and et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
10. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211
11. A.V. Khera, M. Cuchel, M. Llera-Moya, and et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
12. X.M. Li, W.H. Tang, M.K. Mosior, and et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks Arterioscler Thromb Vasc Biol 33 2013 1696 1705
13. A. Rohatgi, A. Khera, J.D. Berry, and et al. HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 2014 2383 2393
14. E. Favari, M. Lee, L. Calabresi, and et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein J Biol Chem 279 2004 9930 9936
15. M. Llera-Moya, D. Drazul-Schrader, B.F. Asztalos, and et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages Arterioscler Thromb Vasc Biol 30 2010 796 801
16. A.R. Tall, L. Yvan-Charvet, N. Terasaka, and et al. HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis Cell Metab 7 2008 365 375
17. R.S. Rosenson, H.B. Brewer Jr., M.J. Chapman, and et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events Clin Chem 57 2011 392 410
18. M. Westerterp, A.E. Bochem, L. Yvan-Charvet, and et al. ATP-binding cassette transporters, atherosclerosis, and inflammation Circ Res 114 2014 157 170
19. P.M. O'Connor, J.M. Naya-Vigne, P.N. Duchateau, and et al. Measurement of prebeta-1 HDL in human plasma by an ultrafiltration-isotope dilution technique Anal Biochem 251 1997 234 240
20. L.T. Guey, C.R. Pullinger, B.Y. Ishida, and et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease Am J Cardiol 108 2011 360 366
21. B.F. Asztalos, C.H. Sloop, L. Wong, and et al. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations Biochim Biophys Acta 1169 1993 291 300
22. B.F. Asztalos, P.S. Roheim, R.L. Milani, and et al. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease Arterioscler Thromb Vasc Biol 20 2000 2670 2676
23. R. Out, W. Jessup, G.W. Le, and et al. Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1 Circ Res 102 2008 113 120
24. L. Yvan-Charvet, M. Ranalletta, N. Wang, and et al. Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice J Clin Invest 117 2007 3900 3908
25. D. Saleheen, R. Scott, S. Javad, and et al. HDL cholesterol efflux capacity is inversely associated with incident CHD events independent of HDL-C and apoA-I Concentrations (abstr) Circulation 130 2014 A19753
26. L. Calabresi, P. Nilsson, E. Pinotti, and et al. A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred Atherosclerosis 205 2009 506 511
27. E.J. Niesor, G.G. Schwartz, A. Perez, and et al. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein Cardiovasc Drugs Ther 29 2015 7 14
28. L. Yvan-Charvet, F. Matsuura, N. Wang, and et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL Arterioscler Thromb Vasc Biol 27 2007 1132 1138
29. P. Barter, A.M. Gotto, J.C. LaRosa, and et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
30. L. Yvan-Charvet, J. Kling, T. Pagler, and et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib Arterioscler Thromb Vasc Biol 30 2010 1430 1438
31. K.K. Ray, M. Ditmarsch, D. Kallend, and et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial Eur Heart J 35 2014 1792 1800
32. W. Wang, W. Song, Y. Wang, and et al. HMG-CoA reductase inhibitors, simvastatin and atorvastatin, downregulate ABCG1-mediated cholesterol efflux in human macrophages J Cardiovasc Pharmacol 62 2013 90 98
33. P.H. Jones, M.H. Davidson, E.A. Stein, and et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR∗Trial) Am J Cardiol 92 2003 152 160